Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain; Laboratory of Regenerative Therapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Laboratory of Regenerative Therapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Neurobiol Dis. 2014 Feb;62:250-9. doi: 10.1016/j.nbd.2013.09.014. Epub 2013 Sep 27.
Much controversy exists concerning the effect of levodopa on striatal dopaminergic markers in Parkinson's disease (PD) and its influence on functional neuroimaging. To deal with this issue we studied the impact of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and chronic levodopa administration on striatal (18)F-DOPA uptake (Ki) in an animal model of PD. The levels of several striatal dopaminergic markers and the number of surviving dopaminergic neurons in the substantia nigra (SN) were also assessed. Eleven Macaca fascicularis were included in the study. Eight animals received weekly intravenous injections of MPTP for 7weeks and 3 intact animals served as controls. MPTP-monkeys were divided in two groups. Group I was treated with placebo while Group II received levodopa. Both treatments were maintained for 11months and then followed by a washout period of 6months. (18)F-DOPA positron emission tomography (PET) scans were performed at baseline, after MPTP intoxication, following 11months of treatment, and after a washout period of 1, 3 and 6months. Monkeys were sacrificed 6months after concluding either placebo or levodopa treatment and immediately after the last (18)F-DOPA PET study. Striatal dopamine transporter (DAT) content, tyrosine hydroxylase (TH) content and aromatic l-amino acid decarboxylase (AADC) content were assessed. In Group II (18)F-DOPA PET studies performed at 3 and 6months after interrupting levodopa showed a significantly increased Ki in the anterior putamen as compared to Group I. Levodopa and placebo treated animals exhibited a similar number of surviving dopaminergic cells in the SN. Striatal DAT content was equally reduced in both groups of animals. Animals in Group I exhibited a significant decrease in TH protein content in all the striatal regions assessed. However, in Group II, TH levels were significantly reduced only in the anterior and posterior putamen. Surprisingly, in the levodopa-treated animals the TH levels in the posterior putamen were significantly lower than those in the placebo group. AADC levels in MPTP groups were similar to those of control animals in all striatal areas analyzed. This study shows that chronic levodopa administration to monkeys with partial nigrostriatal degeneration followed by a washout period induces modifications in the functional activity of the dopaminergic nigrostriatal pathway.
关于左旋多巴对帕金森病(PD)纹状体多巴胺能标志物的影响及其对功能神经影像学的影响存在很多争议。为了应对这一问题,我们在 PD 的动物模型中研究了神经毒素 1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)和慢性左旋多巴给药对纹状体(18)F-DOPA 摄取(Ki)的影响。还评估了几种纹状体多巴胺能标志物的水平和黑质(SN)中存活的多巴胺能神经元的数量。研究纳入了 11 只食蟹猴。8 只动物每周接受静脉注射 MPTP 共 7 周,3 只完整动物作为对照。MPTP 猴分为两组。第 I 组接受安慰剂治疗,第 II 组接受左旋多巴治疗。两种治疗均持续 11 个月,然后进行 6 个月的洗脱期。在基线、MPTP 中毒后、11 个月治疗后以及洗脱期 1、3 和 6 个月后进行(18)F-DOPA 正电子发射断层扫描(PET)扫描。在结束安慰剂或左旋多巴治疗后立即进行最后一次(18)F-DOPA PET 研究后,6 个月处死猴子。评估纹状体多巴胺转运体(DAT)含量、酪氨酸羟化酶(TH)含量和芳香族 l-氨基酸脱羧酶(AADC)含量。在中断左旋多巴后 3 个月和 6 个月进行的第 II 组(18)F-DOPA PET 研究显示,前壳核的 Ki 明显高于第 I 组。接受左旋多巴和安慰剂治疗的动物在 SN 中具有相似数量的存活多巴胺能细胞。两组动物的纹状体 DAT 含量均等量减少。第 I 组动物的所有评估纹状体区域的 TH 蛋白含量均显著降低。然而,在第 II 组中,TH 水平仅在前部和后部壳核显著降低。令人惊讶的是,在接受左旋多巴治疗的动物中,后壳核的 TH 水平明显低于安慰剂组。在所有分析的纹状体区域中,MPTP 组的 AADC 水平与对照组动物相似。这项研究表明,对部分黑质纹状体变性的猴子进行慢性左旋多巴给药,随后进行洗脱期,会导致多巴胺能黑质纹状体通路的功能活性发生改变。